Path2Cures speakers call for open data sharing

Path2Cures speakers call for open data sharing

Originally posted on MedCity News

Breaking out of research silos and collaborating more openly will be a big step in driving personalized medicine forward, said Dr. Andrew Futreal, a professor of genomic medicine at MD Anderson.

(more…)

View On WordPress

Making Breast Cancer Treatments Cheaper & Faster

Making Breast Cancer Treatments Cheaper & Faster

Heart Love

Scientists waging war against breast cancer have a new reason to smile.

Researchers at Lawrence Berkeley National Laboratory and Carnegie Mellon University have developed a sophisticated computational method to determine how gene networks are “rewired” at the moment healthy breast cells turn malignant. It also can determine how the cells respond to potential cancer therapy treatments.

(more…)

View On WordPress

Founders Fund Dives into Life Sciences & Nanotechnology

Founders Fund Dives into Life Sciences & Nanotechnology

r-US-DRUG-PRICES-large570

Founders Fund already stands out for backing startups with radical ideas, including CounsylHampton CreekPlanet Labs, and SpaceX. Now the venture firm is making a formal commitment to funding startups in aeronautics, life sciences, nanotechnology, and other geeky realms.

(more…)

View On WordPress

Podcast: Subbu Arumugam, Health Tech & Health 2.0

I sat down with Subbu Arumugam of Health 2.0 last week at 1871. We had a great conversation about the background on Health IT, the different sectors and the challenges they are facing.

Podcast: Subbu Arumugam, Health Tech & Health 2.0

I sat down with Subbu Arumugam of Health 2.0 last week at 1871. We had a great conversation about the background on Health IT, the different sectors and the challenges they are facing.

Biotech IPOs sputter amid downsizings, disappointments and white flags

Biotech IPOs sputter amid downsizings, disappointments and white flags

Image1_630

Six biotechs were expected to go public this week, eyeing nearly $400 million combined, but that potential has so far amounted to one deeply discounted offering, one bottom-of-the-range debut and one outright cancellation.

(more…)

View On WordPress

Tags: Biotech IPO

Improving clinical research with high-speed data transfer technologies

Improving clinical research with high-speed data transfer technologies

doctors-internet

Data access, quantity, and quality drive innovation in clinical research, both for studies across whole populations and for personalized medicine that focuses on an individual’s disease, diagnosis, and response to treatment. New technologies such as Next Generation Sequencing (NGS) for whole genomes and high-resolution slide imaging are creating terabytes of data that were considered too rare or…

View On WordPress

GSK’s, Lundbeck’s venture arms chip in for Atox Bio’s trial of flesh-eating bacteria treatment

GSK’s, Lundbeck’s venture arms chip in for Atox Bio’s trial of flesh-eating bacteria treatment

Crowdfuning-Bank

(Reuters) – Israel-based Atox Bio, a developer of therapeutics for severe infections, said on Thursday it has raised $23 million in an investment round led by SR One, the healthcare venture capital fund of GlaxoSmithKline.

(more…)

View On WordPress

FTC commissioner speaks out against apps collecting health data

FTC commissioner speaks out against apps collecting health data

healthcare-cloud

Federal Trade Commission (FTC) commissioner Julie Brill has some serious reservations about the collection of health data by consumer apps.

She said as much at the The Hill’s Tech in Policy event in Washington DC Wednesday morning. In a nutshell, the Commissioner made clear that she considers collection and use of data to be one and the same — and she thinks there should be heavy restrictions,…

View On WordPress

U.S. paves way for Novartis to copy Amgen biotech drug

U.S. paves way for Novartis to copy Amgen biotech drug

biosimilars

(Reuters) – U.S. regulators have accepted an application by Sandoz – the generics arm of Novartis – seeking approval for a copycat version of Amgen’s drug Neupogen, or filgrastim, for patients with low white blood cell counts.

(more…)

View On WordPress

Obama expected to address inversion deals and tax reform today

Obama expected to address inversion deals and tax reform today

globe

(Reuters) – U.S. President Barack Obama will call on Thursday for an end to a corporate loophole that allows companies to avoid federal taxes by shifting their tax domiciles overseas in deals known as “inversions,” White House officials said.

(more…)

View On WordPress